GlassScriptPhysician profile
Vanessa B Mitchell
NPI 1326597444
$1,804.73
in general payments reported to CMS, 2019-2025
27 companies · $63.09 in 2025
The $63.09 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $411 · 2022: $450 · 2023: $722 · 2024: $159 · 2025: $63.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $252.68 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $226.43 | 2023-2024 | Myfembree |
| Abbvie INC. | $202.21 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $176.42 | 2021-2023 | |
| Evofem Biosciences, INC. | $113.83 | 2021-2022 | |
| Exeltis, USA INC. | $85.17 | 2021-2025 | Slynd |
| Organon LLC | $84.67 | 2021-2022 | |
| Myriad Women'S Health, INC. | $81.12 | 2023 | Myrisk |
| Millicent US INC | $78.63 | 2023-2024 | Femring, Intrarosa |
| Hologic Sales and Service, LLC | $61.96 | 2023 | Novasure, Aptima |
| Astellas Pharma US INC | $55.52 | 2023-2024 | Veozah |
| Agile Therapeutics, INC. | $45.01 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.88 | 2021-2022 | |
| Gynesonics, INC. | $33.63 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Therapeuticsmd, INC. | $31.32 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $29.67 | 2022-2023 | Balcoltra |
| Biogen, INC. | $27.86 | 2025 | Zurzuvae |
| Currax Pharmaceuticals LLC | $23.45 | 2021-2022 | |
| Coopersurgical, INC. | $21.10 | 2025 | Paragard T 380a |
| Aspira Women'S Health INC | $20.99 | 2024 | Ova1 |
| Optumhealth Care Solutions, LLC | $17.85 | 2023 | Vivify Health Care Team Portal |
| Daiichi Sankyo INC. | $17.60 | 2021 | |
| Mylan Pharmaceuticals INC. | $16.00 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.82 | 2022 | |
| Amgen INC. | $15.78 | 2021 | |
| Pfizer INC. | $14.63 | 2022 | |
| Virtus Pharmaceuticals LLC | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.